Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): Progress in supportive care
Author:
- 1 July 1996
- journal article
- review article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 4 (4) , 305-307
Abstract
The dose-limiting toxicity of the widely used anticancer agent, doxorubicin, is a destructive, irreversible and progressive cardiomyopathy. Prevention of this cardiotoxicity without reduction of antitumour efficacy or the production of new toxicities has therefore been a long-time therapeutic goal. It has now been largely achieved by prior administration of dexrazoxane (DXRz; Cardioxane in Europe; Zinecard in North America; ICRF 187). Six randomized, controlled clinical trials in breast and lung cancer and in soft tissue sarcomas of children have shown a 90% reduction in doxorubicin-induced cardiotoxicity. The results of all these trials lead to the conclusion that DXRz permits: (1) cardiotoxic doses of doxorubicin to be given without cardiotoxicity; (2) patients with increased cardiac risk factors to be treated with full doses of dioxorubicin; (3) second-line treatment with other cardiotoxic drugs.Keywords
This publication has 4 references indexed in Scilit:
- Strategies for prevention of anthracycline cardiotoxicityCancer Treatment Reviews, 1993
- ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.Journal of Clinical Oncology, 1992
- REDUCTION OF CHRONIC DOXORUBICIN CARDIOTOXICITY IN DOGS BY PRETREATMENT WITH (+/-)-1,2-BIS(3,5-DIOXOPIPERAZINYL-1-YL)PROPANE (ICRF-187)1981
- Prevention of the Cardiotoxic Effects of Adriamycin and Daunomycin in the Isolated Dog HeartExperimental Biology and Medicine, 1972